UNSPSC 51313424: Chlorpheniramine maleate

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1Q0O9OJ9Z. European Medicines Agency schedules Chlorphenamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01243MIG. Chlorpheniramine maleate generally arises in the molecular formula C16H19CLN2.C4H4O4. The term 'chlorpheniramine maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule chlorpheniramine maleate under HS 29333910.

As of Q4 2014, CHLORPHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Chlorpheniramine maleate bears US NLM identifiers UMLS ID C0699075 and NCI Concept Code C28925. SMILES: CN(C)CCC(C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313424 Chlorpheniramine maleate is a Commodity code representing individual pharmaceutical products supplied to state and local government health and safety programs. The recent opportunities tagged under this code show minimal direct relevance; the three most recent solicitations involve naloxone and drug deactivation systems (Seminole County, Florida), a direct-to-manufacturer prescription program exploration (Texas HHS), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). State and local procurement under this code spans individual state health departments, county public health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The MMCAP solicitation demonstrates demand from health systems across multiple states seeking bulk pharmaceutical supply through established wholesaler networks, while county-level procurement focuses on specific therapeutic products tied to community health initiatives.

Recent activity appears concentrated in the upper Midwest and Southeast, with the MMCAP cooperative purchasing vehicle serving Minnesota and Oregon and Seminole County, Florida representing southern regional demand. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, due March 26, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and contract terms of two years for new vendors. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, due July 26, 2023, for 1,900 units of naloxone annually with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, though this remains in information-gathering phase rather than formal procurement. Vendors competing under this code should anticipate established wholesaler relationships, compliance with cGMP and Drug Supply Chain Security Act requirements, and pricing models ranging from flat-fee to net pricing structures across cooperative and standalone jurisdictional solicitations.